Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Primary Membranous Nephropathy
CTR20254655Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in idiopathic membranous glomerulonephritis (IMG), sponsored by Hengrui Therapeutics. Started Nov 2025; status: active.
02
Drugs
SHR-2173
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20254655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254655.